Molecular alterations in pancreatic tumors

doi:10.3748/wjg.v27.i21.2710

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 27, Issue 21

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (5794)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Tables (1-3) series.

Item

Count

PDF

453

WORD

262

HTML

3509

Tables (1-3)

273

Sum=4497

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

422

Download

875

Sum=1297

Jun 7, 2021 (publication date) through Nov 18, 2024

Times Cited of This Article

Times Cited (16)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Gastroenterol. Jun 7, 2021; 27(21): 2710-2726
Published online Jun 7, 2021. doi: 10.3748/wjg.v27.i21.2710

Table 2 Main genetic alterations detectable in cystic pancreatic lesions

Type of pancreatic lesion	Genetic alteration	Reported frequency (%)	Type of alterations	Role in clinical practice
IPMN	KRAS	90	Point mutations	Diagnostic
	TP53	10	Point mutations/LOH	Prognostic
	GNAS	40-60	Point mutations	Diagnostic
	RNF43	25	Point mutations/LOH	Diagnostic
MCN	KRAS	0-25% (LG); 50-90% (HG)	Point mutations	Diagnostic
	CDKN2A/p16	0-10 (LG); 50 (HG)	Point mutations/LOH	Prognostic
	TP53	0 (LG); 20-50 (HG)	Point mutations/LOH	Prognostic
SCN	VHL	40-60	Point mutations/LOH	Diagnostic

The percentages quoted are estimated from the literature cited in the paper. Diagnostic role appears mainly in preoperative material. IPMN: Intraductal papillary mucinous neoplasms; MCN: Mucinous cystic neoplasia; LG: Low-grade mucinous cystic neoplasia; HG: High-grade mucinous cystic neoplasia; SCN: Serous cystic neoplasm; LOH: Loss of heterozygosity.

Citation: Visani M, Acquaviva G, De Leo A, Sanza V, Merlo L, Maloberti T, Brandes AA, Franceschi E, Di Battista M, Masetti M, Jovine E, Fiorino S, Pession A, Tallini G, de Biase D. Molecular alterations in pancreatic tumors. World J Gastroenterol 2021; 27(21): 2710-2726
URL: https://www.wjgnet.com/1007-9327/full/v27/i21/2710.htm
DOI: https://dx.doi.org/10.3748/wjg.v27.i21.2710